KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Research & Development: 2010-2025

Historic Research & Development for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $13.5 million.

  • Emergent BioSolutions' Research & Development fell 2.17% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 44.84%. This contributed to the annual value of $70.7 million for FY2024, which is 36.54% down from last year.
  • Emergent BioSolutions' Research & Development amounted to $13.5 million in Q3 2025, which was up 8.00% from $12.5 million recorded in Q2 2025.
  • Emergent BioSolutions' Research & Development's 5-year high stood at $52.5 million during Q1 2021, with a 5-year trough of $9.1 million in Q4 2024.
  • Its 3-year average for Research & Development is $20.3 million, with a median of $15.1 million in 2025.
  • Over the last 5 years, Emergent BioSolutions' Research & Development had its largest YoY gain of 25.77% in 2024, and its largest YoY loss of 69.05% in 2024.
  • Emergent BioSolutions' Research & Development (Quarterly) stood at $38.2 million in 2021, then rose by 23.04% to $47.0 million in 2022, then slumped by 37.45% to $29.4 million in 2023, then crashed by 69.05% to $9.1 million in 2024, then dropped by 2.17% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $12.5 million for Q2 2025, and $15.1 million during Q1 2025.